The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX with or without cetuximab:  NCCTG N0147.
Frank A. Sinicrope
No relevant relationships to disclose
Michelle R. Mahoney
No relevant relationships to disclose
Thomas C. Smyrk
No relevant relationships to disclose
Stephen N. Thibodeau
No relevant relationships to disclose
Richard M. Goldberg
Research Funding - Sanofi
Garth D. Nelson
No relevant relationships to disclose
Daniel J. Sargent
No relevant relationships to disclose
Steven R. Alberts
No relevant relationships to disclose